Diabetes Tied To Greater Death Risk In China

Diabetes Tied to Greater Death Risk in China

Diabetes Tied to Greater Death Risk in China

Diabetes was linked to a rise in all-cause and cause-specific mortality among a Chinese population, researchers stated.
The nationwide study of people in rural and urban areas of China reported a significant association between diabetes and all-cause mortality compared to those without diabetes (1,373 versus 646 deaths/100,000 adjusted rate ratio 2.00, 95% CI 1.93-2.08), which resulted in an average of 9-year shorter lifespan, according to Fiona Bragg, DPhil, of the University of Oxford in England, and colleagues.
Although prevalence rates of diabetes were higher among urban areas of China, mortality rates were higher in rural areas (rural RR 2.17, 95% CI 2.07-2.29), they wrote in the Journal of the American Medical Association.
The authors also found a link between an increased risk for several cardiovascular and non-cardiovascular cause-specific mortalities associated with diabetes.
China, which has one of the highest rates of diabetes in the world with an estimated 110 million individuals affected, has experienced a rapid increase in diabetes prevalence over the past few decades, explained Bragg in an interview with MedPage Today.
"Because the increase in diabetes prevalence in China is recent, the full effect on mortality is unknown. Most previous studies looking at the impact of diabetes on mortality have been in high-income countries where diabetes is generally relatively well managed. It is not clear that the findings of these studies can be applied to China, where there are important differences in diabetes and its management compared with the West," she stated.
Usi Continue reading

Rate this article
Total 1 ratings
Intermittent Fasting Reduces Your Diabetes and Heart Disease Risk, Studies Say

Intermittent Fasting Reduces Your Diabetes and Heart Disease Risk, Studies Say

Intermittent Fasting Reduces Your Diabetes and Heart Disease Risk, Studies Say
Did you know that aside from helping you lose weight and supporting your fitness goals, intermittent fasting can also reduce your risk of chronic diseases, particularly heart disease and diabetes?
According to a 2013 review published in the British Journal of Diabetes and Vascular Disease, obese or overweight individuals with type 2 diabetes who fast on consecutive or alternate days not only lost more weight, but also acquired cardioprotective benefits and experienced better heart health.
I believe that this clearly supports the notion that going against the customary "three square meals" a day in favor of intermittent fasting may have superb benefits for your overall health.
Research Confirms How Intermittent Fasting May Be the Key to Fighting Obesity and Diabetes
The report, which evaluated the various approaches to intermittent fasting, particularly its benefits and limitations in fighting type 2 diabetes and obesity, found that fasting had a broad range of therapeutic potential. These effects were seen even though the total calorie intake of the subjects did not change or was only slightly reduced.
The review suggests that intermittent fasting may also play a role in:
Reducing LDL and total cholesterol levels
Helping modulate levels of visceral fat, the dangerous fat that gathers around your internal organs
Intermittent Fasting Is Not a Diet It's a Lifestyle
While most people would think that intermittent fasting is a fairly new approach to healthy living, this type of lifestyle Continue reading

New Diabetes Technology: Fact and Fantasy

New Diabetes Technology: Fact and Fantasy

Home / Resources / Articles / New Diabetes Technology: Fact and Fantasy
New Diabetes Technology: Fact and Fantasy
Guest Post by David Kliff, Diabetic Investor
Diabetes technology is evolving in a very exciting way, said Jeff Dachis, CEO and Founder of One Drop. But not surprisingly for the vast majority of people with diabetes worldwide, expensive sensors, automated insulin delivery solutions, or call center approaches to care can create barriers and challenges to effective disease management. This statement came from a MannKind press release announcing a new clinical trial.
Appropriate people with type 2 diabetes who meet inclusion criteria will be randomized to one of two treatment arms: Afrezza with One Drop | Premium or One Drop | Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction, and other metrics will be assessed.
Now before we get into whats really going on here I have a few quick thoughts about this trial. First, it is refreshing to see One Drop participate in a real randomized controlled clinical trial, as they have tended to use self-reported data to prove their system works. Two, I suspect that when this trial is over both groups will show various levels of improvements in HbA1c. As I keep saying Afrezza does work; this has never been in dispute. The problems with Afrezza have nothing to do with whether it works. Third, the results of this trial will do nothing to change the fortunes of MannKind or One Drop.
What I found interesting was Mr. Dachis choice of words, as he has drawn a line in the sand. Expensive Continue reading

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Abd Tahrani is a UK National Institute for Health Research Clinician Scientist and Honorary Consultant Physician at the University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK. He has undertaken research into the pathogenesis of diabetes-related microvascular complications, the pathogenesis and management of obesity, the metabolic consequences of sleep-related disorders and the pharmacology of diabetes.
Anthony Barnett is Emeritus Professor of Medicine and Honorary Consultant Physician at the University of Birmingham and Heart of England NHS Foundation Trust, Birmingham, UK. He has undertaken extensive research into the genetics and pathogenesis of type 1 and type 2 diabetes mellitus and associated complications, along with Health Service-related research in ethnic minority groups and the development and use of glucose-lowering therapies. He has been a regular adviser to both the UK National Institute for Health and Care Excellence and the European Medicines Agency.
Clifford Bailey is Professor of Clinical Science at Aston University, Birmingham, UK, and has undertaken extensive research on the pathogenesis of type 2 diabetes mellitus and the development of glucose-lowering therapies. He is an editor of Diabetes and Vascular Disease Research, and has served as an expert witness to medicines regulatory agencies.
Nature Reviews Endocrinology volume 12, pages 566592 (2016)
Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to Continue reading

free online magazine.

free online magazine.

GlucoRx was formed in 2010, although its Sales Director Chris Chapman had been with its sister company, Disposable Medical Equipment Ltd for five years before that. He says, “We set up the company as we could see a way to save the NHS money. We could do that by bringing in products – including blood glucose meters, insulin pen needles and a skin care range – at a reduced cost to the ones they were currently buying. We wanted to bring in more affordable products without losing quality. When we started there were blood glucose meters from four main companies, each of which were charging ~£15 per pot of 50 glucose test strips to go with their meters. We were able to come in and offer our strips at just under £10 per pot.”
Chapman has been with the company since its inception, having previously spent five years in the Royal Navy as a Diver. He also spent 13 years as a Special Constable, finally ending that role in September 2016 due to work pressures, at which point he left the force at the highest position possible, as Chief Officer for Surrey Police.
From the get-go, Chapman sees the biggest challenge he has faced was to break into a market with an unknown name. He recalls, “We had to establish a brand when there were several strong brands already in the space. No one had heard of us, and we had no pedigree in the market place. But the best part has been creating a much better-known name. Our products are now stocked in almost all pharmacies in the UK. It’s great to see our stock on shelves almost everywhere I go, also on television – any fly on the wall docum Continue reading

No more pages to load

Popular Articles

  • New study finds that sitting for protracted periods increases the risk of diabetes, heart disease and death

    Latest news from Loughborough University A new study led by the University of Leicester, in association with colleagues at Loughborough University, has discovered that sitting for long periods increases your risk of diabetes, heart disease and death. The study combined the results of 18 studies and included a total of 794,577 participants. It was led by Dr Emma Wilmot, a research fellow in the Dia ...

  • Man Accused Of Injecting Illegal Drugs At Bus Stop Wants To Raise Greater Awareness Of Diabetes

    A man with Type 1 diabetes is on a mission to raise awareness of the illness, after a passerby thought he was injecting himself with illegal drugs. Ben Lockwood, 26, took to Facebook to explain that his blood sugar levels were high on his way home from work so he gave himself an insulin injection while waiting for the bus. To his surprise, a man nearby remarked: “You can’t do that in a public ...

  • Coffee reduces risk of death from some diseases, Harvard study finds

    People who drink three to five cups of coffee per day are less likely to die prematurely from heart disease, suicide, diabetes or Parkinson's disease, according to research. Both caffeinated and decaffeinated coffee were shown to have benefits, said the study by researchers at the Harvard University Chan School of Public Health published in the latest edition of the journal Circulation. The study ...

  • Are You at Risk for Type 2 Diabetes? Learn Common—and Not So Common—Risk Factors

    Diabetes is not a rare condition – in fact, it’s an epidemic in the U.S. More than 30 million Americans have type 2 diabetes and another 84 million have prediabetes, a condition of elevated blood sugar levels that often leads to type 2. Why do so many Americans have type 2 diabetes? Experts say this major public health problem is due to an aging population, increasing obesity rates and rising ...

  • Statins increase the risk of developing diabetes in at-risk people

    Among susceptible individuals, statins — which are a common cholesterol-lowering medication — could increase the risk of type 2 diabetes by 30 percent. These new findings are sure to reignite debate. Statins lower cholesterol by reducing its production in the liver. They do this by blocking an enzyme called hydroxy-methyl-glutaryl-coenzyme A reductase, which is involved in its manufacture. Sta ...

  • Too much sitting linked to heart disease, diabetes, premature death

    Like many people, I have a job that involves sitting in front of a computer most of the day. Because I work from home, I don’t have to sit through a long commute, and my dog gets me up out of my chair for walks a couple times a day. Still, a new study about the health hazards of sitting too much (or what researchers call sedentary behavior) has made me more conscious of how much uninterrupted ch ...

  • Treat type 2 diabetes 'like cancer': How THIS major complication can lead to early death

    "Diabetes can be more significant than many forms of cancer," said Dr David G. Armstrong, professor of surgery and director of the Southern Arizona Limb Salvage Alliance at the University of Arizona College of Medicine – Tucson. "This is a concept that's misaligned right now in medicine. “As we move toward diseases of decay, as I call them — things like cancer, cardiovascular disease, diabet ...

  • Mary Tyler Moore’s death a reminder of the toll of diabetes

    Mary Tyler Moore debuted on television in the 1950s, appearing in commercials that aired during a popular show. Her star continued to rise until Moore landed the eponymous sitcom that became a staple of 1970s pop culture. But it was another event that cast her in a new, unfamiliar and lifelong role: a diagnosis of Type 1 diabetes at age 33. Moore, who died Jan. 25 at age 80, did more than just fig ...

  • Johnson & Johnson’s new diabetes drug linked to coma and death

    A Philadelphia man is suing Johnson & Johnson, claiming the pharmaceutical giant’s diabetes drug, Invokana, damaged his kidneys. Invokana is made by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. The commonly-prescribed drug had only been on the market for two years before the U.S. Food and Drug Administration determined it caused “too much acid in the blood and serious urinary tract ...

Related Articles